<DOC>
	<DOCNO>NCT01121276</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial investigate absorption effect body NN1218 subject type 1 type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating NN1218 Subjects With Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 type 2 diabetes mellitus 12 month Treated multiple daily insulin injection continuous subcutaneous insulin infusion ( CSII ) 12 month long subject type 1 diabetes 3 month long subject type 2 diabetes Body Mass Index ( BMI ) 18.032.0 kg/m2 ( inclusive ) Surgery trauma significant blood loss ( 500 mL ) within last 3 month prior trial start Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>